BioRegenxBRGX Market Cap is $7.38 Mil as of Jul. 09, 2026. The stock has 5 warning signs investors should review. Among 694 Healthcare Providers & Services companies, BioRegenx ranks worse than 86.17% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). BioRegenx's share price for the quarter that ended in Mar. 2026 was $0.01159. BioRegenx's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 969.02 Mil. Therefore, BioRegenx's market cap for the quarter that ended in Mar. 2026 was $11.23 Mil.
BioRegenx's quarterly market cap
declined
from Sep. 2025 ($14.91 Mil) to Dec. 2025 ($12.50 Mil) and
declined
from Dec. 2025 ($12.50 Mil) to Mar. 2026 ($11.23 Mil).
BioRegenx's annual market cap
increased
from Dec. 2023 ($6.50 Mil) to Dec. 2024 ($8.61 Mil) and
increased
from Dec. 2024 ($8.61 Mil) to Dec. 2025 ($12.50 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. BioRegenx's Enterprise Value for Today is $9.50 Mil.
BioRegenx (OTCPK:BRGX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
BioRegenx Market Cap Related Terms
BioRegenx Market Cap Historical Data
* Premium members only.
The historical data trend for BioRegenx's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, BioRegenx's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioRegenx Market Cap vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, BioRegenx's Market Cap distribution charts can be found below:
* The bar in red indicates where BioRegenx's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
BioRegenx's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioRegenx (BRGX) has a Market Cap of $7.38 Mil as of Jul. 09, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BioRegenx and its competitors. According to the industry distribution chart, BioRegenx ranks #598 out of 694 companies in the Healthcare Providers & Services industry, placing it in the top 86.2%.
Is BioRegenx's Market Cap too high?
BioRegenx's current Market Cap is $7.38 Mil. The Healthcare Providers & Services industry median Market Cap is 96.58. BioRegenx's value of $7.38 Mil is 92.4% below this industry median. Based on the distribution chart, BioRegenx ranks #598 out of 694 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does BioRegenx's Market Cap compare to VYND and ACON?
According to the Healthcare Providers & Services industry distribution chart, BioRegenx ranks #598 out of 694 companies for Market Cap. This places BioRegenx in the lower half of its industry. The industry median Market Cap is 96.58. BioRegenx's value of $7.38 Mil is 92.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Healthcare Providers & Services company?
The median Market Cap among Healthcare Providers & Services companies is 96.58, based on 694 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioRegenx's current Market Cap of $7.38 Mil is 92.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BioRegenx and its competitors. For the Healthcare Providers & Services industry, the median Market Cap is 96.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioRegenx's current Market Cap is $7.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRegenx stock overvalued right now?
Based on GuruFocus' analysis, BioRegenx (BRGX) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 24% below its estimated fair value. The current Market Cap is $7.38 Mil and 92.4% below the Healthcare Providers & Services industry median of 96.58. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For BioRegenx (BRGX), the current Market Cap is $7.38 Mil as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioRegenx Inc develops and manufactures medical test equipment and high-quality, science-based nutritional products. The Company distributes wellness devices. The products are sold nationally through a direct selling channel to health professionals and research organizations. The company operates and manages its business as one reportable and operating segment as a medical testing, diagnostic and nutraceutical company. It focuses on commercialization of its patented technologies in its field.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BRGX has been successfully added to your 